HRP20161330T1 - Terapeutski spojevi i odgovarajući postupci upotrebe - Google Patents

Terapeutski spojevi i odgovarajući postupci upotrebe

Info

Publication number
HRP20161330T1
HRP20161330T1 HRP20161330TT HRP20161330T HRP20161330T1 HR P20161330 T1 HRP20161330 T1 HR P20161330T1 HR P20161330T T HRP20161330T T HR P20161330TT HR P20161330 T HRP20161330 T HR P20161330T HR P20161330 T1 HRP20161330 T1 HR P20161330T1
Authority
HR
Croatia
Prior art keywords
methods
therapeutic compounds
therapeutic
compounds
Prior art date
Application number
HRP20161330TT
Other languages
English (en)
Inventor
Masaki Suzuki
Kazumi Kondo
Muneaki Kurimura
Krishna Reddy Valluru
Akira Takahashi
Takeshi Kuroda
Haruka Takahashi
Tae Fukushima
Shin Miyamura
Indranath Ghosh
Abhishek Dogra
Geraldine Harriman
Amy Elder
Satoshi Shimizu
Kevin J. Hodgetts
Jason S. Newcom
Original Assignee
Otsuka Pharmaceutical Co., Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
Priority to US29154409P priority Critical
Priority to US29155409P priority
Priority to US29155009P priority
Priority to EP10841742.9A priority patent/EP2521549B1/en
Priority to PCT/US2010/062555 priority patent/WO2011082337A1/en
Application filed by Otsuka Pharmaceutical Co., Ltd. filed Critical Otsuka Pharmaceutical Co., Ltd.
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44226819&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HRP20161330(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Publication of HRP20161330T1 publication Critical patent/HRP20161330T1/hr

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12Antidiarrhoeals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10Drugs for genital or sexual disorders; Contraceptives for impotence
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/06Antimigraine agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/20Hypnotics; Sedatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/26Psychostimulants, e.g. nicotine, cocaine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32Alcohol-abuse
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36Opioid-abuse
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or anti-inflammatory agents, e.g antirheumatic agents; Non-steroidal anti-inflammatory drugs (NSAIDs)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00General protective or antinoxious agents
    • A61P39/02Antidotes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D495/00Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
HRP20161330TT 2009-12-31 2016-10-12 Terapeutski spojevi i odgovarajući postupci upotrebe HRP20161330T1 (hr)

Priority Applications (5)

Application Number Priority Date Filing Date Title
US29154409P true 2009-12-31 2009-12-31
US29155409P true 2009-12-31 2009-12-31
US29155009P true 2009-12-31 2009-12-31
EP10841742.9A EP2521549B1 (en) 2009-12-31 2010-12-30 Therapeutic compounds and related methods of use
PCT/US2010/062555 WO2011082337A1 (en) 2009-12-31 2010-12-30 Therapeutic compounds and related methods of use

Publications (1)

Publication Number Publication Date
HRP20161330T1 true HRP20161330T1 (hr) 2016-12-30

Family

ID=44226819

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20161330TT HRP20161330T1 (hr) 2009-12-31 2016-10-12 Terapeutski spojevi i odgovarajući postupci upotrebe

Country Status (27)

Country Link
US (3) US9073890B2 (hr)
EP (2) EP3056207B1 (hr)
JP (3) JP5753194B2 (hr)
KR (1) KR20120115350A (hr)
CN (2) CN102883723B (hr)
AR (1) AR079814A1 (hr)
AU (2) AU2010339423C1 (hr)
CA (1) CA2785923C (hr)
CO (1) CO6571895A2 (hr)
CY (1) CY1118249T1 (hr)
DK (1) DK2521549T3 (hr)
EA (2) EA201790962A1 (hr)
ES (1) ES2598577T3 (hr)
HK (1) HK1173654A1 (hr)
HR (1) HRP20161330T1 (hr)
HU (1) HUE030752T2 (hr)
IL (1) IL219974D0 (hr)
LT (1) LT2521549T (hr)
MX (2) MX349476B (hr)
MY (1) MY161082A (hr)
PH (1) PH12015502823A1 (hr)
PL (1) PL2521549T3 (hr)
PT (1) PT2521549T (hr)
SG (2) SG10201408789WA (hr)
SI (1) SI2521549T1 (hr)
TW (2) TWI591063B (hr)
WO (1) WO2011082337A1 (hr)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LT2473487T (lt) 2009-09-03 2017-01-10 Bristol-Myers Squibb Company Chinazolinai kaip kalio jonų kanalų inhibitoriai
GB2497476B (en) 2010-09-06 2018-01-10 Guangzhou Inst Biomed & Health Amide Compounds
JP6121658B2 (ja) * 2011-06-29 2017-04-26 大塚製薬株式会社 治療用化合物、及び関連する使用の方法
MX2013015204A (es) * 2011-06-29 2014-02-17 Otsuka Pharma Co Ltd Quinazolinas como compuestos terapeuticos, y metodos de uso relacionados.
US9173395B2 (en) * 2011-07-04 2015-11-03 Bayer Intellectual Property Gmbh Use of substituted isoquinolinones, isoquinolindiones, isoquinolintriones and dihydroisoquinolinones or in each case salts thereof as active agents against abiotic stress in plants
WO2013013614A1 (zh) * 2011-07-28 2013-01-31 南京英派药业有限公司 4-(3-杂芳基芳基氨基)喹唑啉和1-(3-杂芳基芳基氨基)异喹啉作为Hedgehog通路抑制剂及其应用
WO2013182580A1 (en) * 2012-06-07 2013-12-12 F. Hoffmann-La Roche Ag Pyrrolopyrimidone and pyrrolopyridone inhibitors of tankyrase
NZ703632A (en) 2012-06-11 2016-01-29 Squibb Bristol Myers Co Phosphoramidic acid prodrugs of 5-[5-phenyl-4-(pyridin-2-ylmethylamino)quinazolin-2-yl]pyridine-3-sulfonamide
CN102702116B (zh) * 2012-06-13 2014-12-31 华南理工大学 4-(3-氯-4-甲氧基苯胺基)-6-(3-胺基苯基)喹唑啉类化合物或其药学上可接受的盐和制备方法与应用
EP2970199A1 (en) 2013-03-11 2016-01-20 Bristol-Myers Squibb Company Isoquinolines as potassium ion channel inhibitors
CA2905451A1 (en) 2013-03-14 2014-10-02 Convergene Llc Methods and compositions for inhibition of bromodomain-containing proteins
SG11201602446VA (en) * 2013-10-16 2016-05-30 Shanghai Yingli Pharmaceutical Co Ltd Fused heterocyclic compound, preparation method therefor, pharmaceutical composition, and uses thereof
JP6474166B2 (ja) 2014-01-01 2019-02-27 メディベイション テクノロジーズ エルエルシー 化合物及び使用方法
EP3233085A4 (en) 2014-12-15 2018-06-13 The Regents of The University of Michigan Small molecule inhibitors of egfr and pi3k
CA3006300A1 (en) 2015-11-25 2017-06-01 Convergene Llc Bicyclic bet bromodomain inhibitors and uses thereof
CN107722012B (zh) * 2016-08-11 2020-05-29 斯福瑞(南通)制药有限公司 制备4-氯-7H-吡咯并[2,3-d]嘧啶的方法
CA3046339A1 (en) 2016-12-20 2018-06-28 Astrazeneca Ab Amino-triazolopyridine compounds and their use in treating cancer
AU2018378348A1 (en) 2017-12-05 2020-06-18 Sunovion Pharmaceuticals Inc. Crystal forms and production methods thereof
US10369134B2 (en) 2017-12-05 2019-08-06 Sunovion Pharmaceuticals Inc. Nonracemic mixtures and uses thereof
WO2020021064A1 (en) 2018-07-26 2020-01-30 Domain Therapeutics Substituted quinazolinone derivatives and their use as positive allosteric modulators of mglur4

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2657760B2 (ja) 1992-07-15 1997-09-24 小野薬品工業株式会社 4−アミノキナゾリン誘導体およびそれを含有する医薬品
US20020025968A1 (en) 1998-04-15 2002-02-28 Rifat Pamukcu Method for inhibiting neoplastic cells and related conditions by exposure to 4-aminoquinazoline derivatives
CN1186324C (zh) * 2000-04-27 2005-01-26 山之内制药株式会社 稠合杂芳基衍生物
WO2002062767A1 (fr) 2001-02-07 2002-08-15 Sumitomo Pharmaceuticals Company, Limited Nouveaux derives de quinazoline
AU2002250394A1 (en) 2001-03-23 2002-10-08 Bayer Corporation Rho-kinase inhibitors
WO2003000188A2 (en) 2001-06-21 2003-01-03 Ariad Pharmaceuticals, Inc. Novel quinazolines and uses thereof
DE60320933D1 (de) 2002-01-10 2008-06-26 Bayer Healthcare Ag Rho-kinase inhibitoren
RS63204A (en) * 2002-01-17 2006-10-27 Neurogen Corporation Substituted quinazolin-4-ylamine analogues as modulators of capsaicin
CA2509616A1 (en) * 2002-12-13 2004-07-01 Neurogen Corporation Combination therapy for the treatment of pain
JP2006515846A (ja) * 2002-12-13 2006-06-08 ニューロジェン・コーポレーション カプサイシン受容体モジュレーターとしての2−置換キナゾリン−4−イルアミン類似体
WO2004065392A1 (en) * 2003-01-24 2004-08-05 Smithkline Beecham Corporation Condensed pyridines and pyrimidines and their use as alk-5 receptor ligands
CL2004000409A1 (es) 2003-03-03 2005-01-07 Vertex Pharma Compuestos derivados de 2-(cilo sustituido)-1-(amino u oxi sustituido)-quinazolina, inhibidores de canales ionicos de sodio y calcio dependientes de voltaje; composicion farmaceutica; y uso del compuesto en el tratamiento de dolor agudo, cronico, neu
CA2520323C (en) * 2003-04-09 2013-07-09 Exelixis, Inc. Tie-2 modulators and methods of use
US20090143399A1 (en) 2003-10-14 2009-06-04 Arizona Board Of Regents On Behalf Of The University Of Arizona Protein Kinase Inhibitors
WO2005042501A1 (en) 2003-11-03 2005-05-12 Warner-Lambert Company Llc Novel norepinephrine reuptake inhibitors for the treatment of central nervous system disorders
EP1702077A4 (en) * 2003-12-08 2007-10-31 Pfizer Interaction of nmda receptor with the protein tyrosine phosphatase step in psychotic disorders
EP1742634B1 (en) * 2004-04-13 2010-10-27 ICAgen, Inc. Polycyclic pyrimidines as potassium ion channel modulators
WO2006058201A2 (en) 2004-11-23 2006-06-01 Reddy Us Therapeutics, Inc. Heterocyclic and bicyclic compounds, compositions and methods
JP2007084494A (ja) 2005-09-22 2007-04-05 Oncorex Inc Pim−1活性阻害剤
GB0524436D0 (en) 2005-11-30 2006-01-11 Novartis Ag Organic compounds
JP2009519995A (ja) * 2005-12-20 2009-05-21 ノイロサーチ アクティーゼルスカブ 呼吸器疾患の治療のためのカリウムチャンネル調節剤としての2−ピリジン−2−イル−キナゾリン誘導体
JP5738516B2 (ja) 2005-12-30 2015-06-24 ゼンサン (シャンハイ) サイエンス アンド テクノロジー リミテッド 心機能改善のためのニューレグリンの徐放
DE102006012251A1 (de) 2006-03-15 2007-11-08 Grünenthal GmbH Substituierte 4-Amino-chinazolin-Derivate und ihre Verwendung zur Herstellung von Arzneimitteln
AU2007249762A1 (en) 2006-05-15 2007-11-22 Senex Biotechnology, Inc Identification of CDKI pathway inhibitors
US9259426B2 (en) 2006-07-20 2016-02-16 Gilead Sciences, Inc. 4,6-di- and 2,4,6-trisubstituted quinazoline derivatives useful for treating viral infections
WO2008092862A1 (en) * 2007-01-30 2008-08-07 Janssen Pharmaceutica N.V. Bicyclic derivatives as ep4 agonists
US20100152210A1 (en) 2007-03-28 2010-06-17 Neuro Search A/S/ Purinyl derivatives and their use as potassium channel modulators
JP2010522721A (ja) 2007-03-28 2010-07-08 ノイロサーチ アクティーゼルスカブ プリニル誘導体及びカリウムチャネルモジュレーターとしてのそれらの使用
US20090023773A1 (en) 2007-06-27 2009-01-22 Painceptor Pharma Corporation Compositions and methods for modulating gated ion channels
CN101932587A (zh) 2007-09-24 2010-12-29 吉宁特有限公司 噻唑并嘧啶pi3k抑制剂化合物及使用方法
GB0724349D0 (en) 2007-12-13 2008-01-30 Prolysis Ltd Antibacterial agents
CA2711759A1 (en) 2008-01-30 2009-08-06 Genentech, Inc. Pyrazolopyrimidine pi3k inhibitor compounds and methods of use
US20090192176A1 (en) 2008-01-30 2009-07-30 Wyeth 1H-PYRAZOLO[3,4-D]PYRIMIDINE, PURINE, 7H-PURIN-8(9H)-ONE, 3H-[1,2,3]TRIAZOLO[4,5-D]PYRIMIDINE, AND THIENO[3,2-D]PYRIMIDINE COMPOUNDS, THEIR USE AS mTOR KINASE AND PI3 KINASE INHIBITORS, AND THEIR SYNTHESES
SG176959A1 (en) 2009-06-24 2012-01-30 Genentech Inc Oxo-heterocycle fused pyrimidine compounds, compositions and methods of use
US20110077250A1 (en) 2009-06-26 2011-03-31 Ryder Sean Compounds for modulating rna binding proteins and uses therefor
EP2464647B1 (en) 2009-08-11 2016-09-21 Bristol-Myers Squibb Company Azaindazoles as btk kinase modulators and use thereof
LT2473487T (lt) 2009-09-03 2017-01-10 Bristol-Myers Squibb Company Chinazolinai kaip kalio jonų kanalų inhibitoriai
AU2010313622B2 (en) 2009-11-02 2014-08-14 Ahr Pharmaceuticals, Inc. ITE for cancer intervention and eradication

Also Published As

Publication number Publication date
IL219974D0 (en) 2012-07-31
EA201290593A1 (ru) 2013-12-30
US9630947B2 (en) 2017-04-25
JP6062999B2 (ja) 2017-01-18
US20170217923A1 (en) 2017-08-03
CN105218516A (zh) 2016-01-06
JP2015178517A (ja) 2015-10-08
MY161082A (en) 2017-04-14
JP5753194B2 (ja) 2015-07-22
JP2017071639A (ja) 2017-04-13
WO2011082337A8 (en) 2012-07-05
AU2010339423A1 (en) 2012-06-14
MX2012007727A (es) 2012-11-22
LT2521549T (lt) 2016-11-10
CN102883723B (zh) 2015-09-16
TWI601723B (zh) 2017-10-11
SG181523A1 (en) 2012-07-30
CO6571895A2 (es) 2012-11-30
KR20120115350A (ko) 2012-10-17
DK2521549T3 (en) 2016-11-14
ES2598577T3 (es) 2017-01-27
US20130053341A1 (en) 2013-02-28
CA2785923C (en) 2017-06-06
CA2785923A1 (en) 2011-07-07
SG10201408789WA (en) 2015-02-27
EP2521549A1 (en) 2012-11-14
SI2521549T1 (sl) 2017-01-31
TW201630898A (zh) 2016-09-01
EP2521549A4 (en) 2013-06-05
AR079814A1 (es) 2012-02-22
EP2521549B1 (en) 2016-08-17
CN102883723A (zh) 2013-01-16
EP3056207A1 (en) 2016-08-17
EP3056207B1 (en) 2018-06-20
PL2521549T3 (pl) 2017-01-31
AU2017201175A1 (en) 2017-03-16
WO2011082337A1 (en) 2011-07-07
AU2010339423C1 (en) 2017-03-09
CY1118249T1 (el) 2017-06-28
AU2010339423B2 (en) 2016-12-01
TW201124395A (en) 2011-07-16
HUE030752T2 (en) 2017-05-29
TWI591063B (zh) 2017-07-11
US20150307477A1 (en) 2015-10-29
MX349476B (es) 2017-07-31
AU2010339423B9 (en) 2016-12-22
PT2521549T (pt) 2016-10-14
JP2013516428A (ja) 2013-05-13
PH12015502823A1 (en) 2018-01-22
HK1173654A1 (zh) 2017-07-07
EA201790962A1 (ru) 2018-04-30
US9073890B2 (en) 2015-07-07
EA028066B1 (ru) 2017-10-31

Similar Documents

Publication Publication Date Title
IL266168D0 (en) Heteroaryl compounds and methods of use thereof
HRP20181615T1 (hr) Terapijsko sredstvo koje izaziva citotoksičnost
IL249941D0 (en) Spiro-oxindole compounds and their use as therapeutic agents
IL248530D0 (en) Biomarkers and methods of treatment
IL252699D0 (en) Treatment of multiple sclerosis with laquinimod
HRP20160997T1 (hr) Liječenje poremećaja povezanih s bdnf primjenom lakvinimoda
IL256924D0 (en) Prebiotic formulations and methods of use
IL249102D0 (en) Melatonin tablet and methods of preparation and use
HRP20141047T1 (hr) Pripravci za sužavanje krvnih žila i metode njihove uporabe
IL250314D0 (en) Enantiomers of spiro-oxindole compounds and their uses as therapeutic agents
HRP20151002T1 (en) 5-anilinoimidazopyridines and methods of use
HRP20171352T1 (hr) Wnt-antagonisti i postupci liječenja
HK1200745A1 (en) Medical connectors and methods of use
ZA201308859B (en) Quinazolines as therapeutic compounds and related methods of use
ZA201304280B (en) Treatment of jak2-mediated conditions
HK1247911A1 (zh) 多環化合物及其使用方法
HK1180326A1 (zh) 吡啶酮和氮雜吡啶酮化合物及使用方法
EP2685882A4 (en) Tissue retractor and methods of use
SG10201602752XA (en) Melanin modification compositions and methods of use
GB2494493B (en) Patient interface and aspects thereof
IL215402D0 (en) Anti-fcrh5 antibodies and immunoconjugates and methods of use
GB2509641B (en) Patient interface and aspects thereof
ZA201107128B (en) Anti-fcrh5 antibodies and immunoconjugates and methods of use
IL213971D0 (en) Modular dna-binding domains and methods of use
IL217745D0 (en) Antiviral compounds and methods of making and using thereof